Research & Development Service, Veterans Affairs Portland Health Care System, Portland, OR, USA.
Mental Health and Clinical Neurosciences Division, Veterans Affairs Portland Health Care System, Portland, Or, USA.
J Clin Exp Neuropsychol. 2021 Aug;43(6):599-610. doi: 10.1080/13803395.2021.1976734. Epub 2021 Oct 6.
To evaluate whether cognitive performance in adults with active methamphetamine use (MA-ACT) differs from cognitive performance in adults in remission from MA use disorder (MA-REM) and adults without a history of substance use disorder (CTLs).
MA-ACT (n = 36), MA-REM (n = 48), and CTLs (n = 62) completed the Neuropsychological Assessment Battery (NAB).
The MA-ACT group did not perform significantly worse than CTLs on any NAB Index. The MA-REM group performed significantly (p < 0.050) worse than CTLs on the NAB Memory Index. The MA-ACT group performed significantly better than CTLs and the MA-REM group on the Executive Functions Index.
Some cognitive deficits are apparent during remission from MA use, but not during active use; this may result in clinical challenges for adults attempting to maintain recovery and continue with treatment.
评估正在使用甲基苯丙胺(MA-ACT)的成年人与从 MA 使用障碍中缓解的成年人(MA-REM)和没有物质使用障碍史的成年人(CTLs)相比,其认知表现是否存在差异。
MA-ACT(n=36)、MA-REM(n=48)和 CTLs(n=62)完成了神经心理评估电池(NAB)。
MA-ACT 组在任何 NAB 指数上的表现均不比 CTLs 差。MA-REM 组在 NAB 记忆指数上的表现明显(p<0.050)比 CTLs 差。MA-ACT 组在执行功能指数上的表现明显优于 CTLs 和 MA-REM 组。
在 MA 使用缓解期间,一些认知缺陷是明显的,但在活跃使用期间则不是;这可能会对试图保持康复并继续治疗的成年人造成临床挑战。